RxDoctor Payments Data

Wendy Wood Neeson

Family · Sheridan, WYNPI 1699827766

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Lilly USA, LLC at 29.2% of the total. Reporting peaked in 2021 at $458 and has fallen 74.8% since, to $115 in 2025.

$1,258in general payments, 2019–2025

Across 65 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$367
  • AbbVie$338
  • Sanofi-aventis U.S. LLC$161
  • Novo Nordisk$149
  • AstraZeneca$103
  • Corcept Therapeutics$55
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$1,24599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,258 in reported general payments places this provider in the 80th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$2,390
Medicare patients
16
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide13$12,289
OzempicSemaglutide12$9,434
Tresiba Flextouch U-100Insulin Degludec12$5,878
Atorvastatin Calcium15$525
Pravastatin Sodium12$372
Levothyroxine Sodium20$237
Losartan Potassium25$230
Bupropion XlBupropion Hcl17$205
Omeprazole13$186
Amlodipine Besylate16$150
Metformin Hcl ErMetformin Hcl11$76
Citalopram HbrCitalopram Hydrobromide12$57
Hydrochlorothiazide12$19
Simvastatin12$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$149$21,72325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 284 family providers in Wyoming.

Other family in Sheridan

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →